US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Polyrizon Ltd.

8.87

-0.2800-3.06%

Post-market: 9.630.7600+8.57%16:10 EDT

Volume:10.29K

Turnover:92.99K

Market Cap:21.54M

PE:-1.79

High:9.31

Open:9.31

Low:8.70

Close:9.15

52wk High:18.20

52wk Low:2.88

Shares:2.43M

Float Shares:2.13M

Volume Ratio:0.59

T/O Rate:0.48%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.9600

ROE:-21.42%

ROA:-23.30%

PB:0.88

PE(LYR):- -

Loading ...

Overview Company News Filings

Polyrizon Makes Strong Progress: Receives Central Irb Approval for Its Allergy Blocker Clinical Trial

THOMSON REUTERS

Polyrizon says U.S. publishes patent application for Trap & Target nasal drug delivery platform

Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

THOMSON REUTERS

Polyrizon Signs Agreements for Nasarix Human Study

MT Newswires Live

Polyrizon - Agrees With European Medical Center and Cro for Nasarix Human Study

THOMSON REUTERS

Polyrizon signs contracts with European medical center, CRO for NASARIX nasal residence-time study

Polyrizon says European patent application for mucoadhesive nasal drug delivery technology is published

Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology

THOMSON REUTERS

Polyrizon announces annual shareholder meeting

Polyrizon signs deals with two additional US clinical sites for NASARIX trial

Polyrizon Advances Nasarix Study With 3 Major US Trial Sites

MT Newswires Live

Polyrizon signs agreements with two additional clinical sites for Nasarix study

Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for Nasarix™ Trial

THOMSON REUTERS

Polyrizon: Co & Arrow Aviation Entered Into Letter Agreement Extending Exclusivity Period & Initial Negotiation Period Under Mou to June 30

THOMSON REUTERS

Polyrizon appoints Ami Oren as Class I director

Polyrizon signs first U.S. clinical trial agreement for NASARIX allergy blocker study

Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for Nasarix™ Allergy Blocker Clinical Trial

THOMSON REUTERS

Polyrizon expands U.S. patent claims for intranasal drug delivery platform

Polyrizon Ltd trading halted, volatility trading pause

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:58 AM

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/PLRZ/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PLRZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","market":"US","secType":"STK","nameCN":"Polyrizon Ltd.","latestPrice":8.87,"timestamp":1791489600000,"preClose":9.15,"halted":0,"volume":10287,"hourTrading":{"tag":"盘后","latestPrice":9.63,"preClose":8.87,"latestTime":"16:10 EDT","volume":6,"amount":54.46379999999999,"timestamp":1791490204817,"change":0.76,"changeRate":0.085682,"amplitude":0.043269},"delay":0,"changeRate":-0.030601092896174985,"floatShares":2131700,"shares":2428604,"eps":-4.96,"marketStatus":"Post-Mkt","change":-0.28,"latestTime":"10-08 16:33:58 EDT","open":9.31,"high":9.31,"low":8.7,"amount":92988,"amplitude":0.066667,"askPrice":10.47,"askSize":36,"bidPrice":8.6,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-4.96,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791504000000},"marketStatusCode":4,"adr":0,"listingDate":1730174400000,"exchange":"NASDAQ","adjPreClose":9.15,"preHourTrading":{"tag":"盘前","latestPrice":9.85,"preClose":9.15,"latestTime":"05:11 EDT","volume":3,"amount":30.850002,"timestamp":1791450703105,"change":0.7,"changeRate":0.076503,"amplitude":0.071038},"postHourTrading":{"tag":"盘后","latestPrice":9.63,"preClose":8.87,"latestTime":"16:10 EDT","volume":6,"amount":54.46379999999999,"timestamp":1791490204817,"change":0.76,"changeRate":0.085682,"amplitude":0.043269},"volumeRatio":0.592426},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","floatShares":2131700,"roa":"-23.30%","roe":"-21.42%","lyrEps":0,"volumeRatio":0.592426,"shares":2428604,"dividePrice":0,"high":9.31,"amplitude":0.066667,"preClose":9.15,"low":8.7,"week52Low":2.88,"pbRate":"0.88","week52High":18.2,"institutionHeld":0,"latestPrice":8.87,"committee":-0.565217,"eps":-4.96,"divideRate":0,"volume":10287,"delay":0,"ttmEps":-4.96,"open":9.31,"prevYearClose":8.49,"prevWeekClose":9.61,"prevMonthClose":10.7831,"prevQuarterClose":10.7831,"fiveDayClose":10.32,"twentyDayClose":11.23,"sixtyDayClose":13.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PLRZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-28","symbol":"PLRZ","defaultRemindTime":1764340200000,"type":"split","dateTimestamp":1764306000000,"forFactor":6,"toFactor":1,"ratio":6},{"market":"US","date":"2025-05-27","symbol":"PLRZ","defaultRemindTime":1748352600000,"type":"split","dateTimestamp":1748318400000,"forFactor":250,"toFactor":1,"ratio":250}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PLRZ\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PLRZ\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PLRZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PLRZ","date":"2026-10-07","current":-1.788306,"percent":0.668737,"low":-29.515607,"twenty":-11.383325,"median":-6.750178,"eighty":-3.170343,"high":-0.011381,"avg":-7.91554,"sd":5.918473,"marketCap":23483872},"quantilePoints":[{"date":"2024-10-31","current":-13.097935,"twenty":-22.948538,"median":-13.097935,"eighty":-12.489816,"marketCap":7858761},{"date":"2024-11-08","current":-3.903419,"twenty":-12.692522,"median":-4.690878,"eighty":-4.316449,"marketCap":3891709},{"date":"2024-11-15","current":-2.661127,"twenty":-9.219549,"median":-4.249136,"eighty":-3.530862,"marketCap":2653144},{"date":"2024-11-22","current":-2.985655,"twenty":-4.737156,"median":-3.736612,"eighty":-3.09924,"marketCap":2976698},{"date":"2024-11-29","current":-3.042447,"twenty":-4.451075,"median":-3.375089,"eighty":-3.037515,"marketCap":3033320},{"date":"2024-12-06","current":-3.212824,"twenty":-4.383762,"median":-3.342636,"eighty":-3.042447,"marketCap":3203186},{"date":"2024-12-13","current":-3.375088,"twenty":-4.191157,"median":-3.358862,"eighty":-3.047315,"marketCap":3364963},{"date":"2024-12-20","current":-7.561496,"twenty":-4.383762,"median":-3.375088,"eighty":-3.07146,"marketCap":7538812},{"date":"2024-12-27","current":-5.744141,"twenty":-5.095085,"median":-3.407542,"eighty":-3.090153,"marketCap":5726909},{"date":"2025-01-03","current":-5.938858,"twenty":-6.101122,"median":-3.569805,"eighty":-3.132991,"marketCap":5921041},{"date":"2025-01-10","current":-4.997727,"twenty":-6.159537,"median":-3.796975,"eighty":-3.146231,"marketCap":4982734},{"date":"2025-01-17","current":-6.142316,"twenty":-6.098128,"median":-3.933764,"eighty":-3.167391,"marketCap":6123889},{"date":"2025-01-24","current":-5.889893,"twenty":-6.192801,"median":-4.333277,"eighty":-3.193353,"marketCap":5872223},{"date":"2025-01-31","current":-5.553327,"twenty":-6.125488,"median":-4.527162,"eighty":-3.214122,"marketCap":5536667},{"date":"2025-02-07","current":-4.552045,"twenty":-6.087615,"median":-4.738105,"eighty":-3.227753,"marketCap":4538389},{"date":"2025-02-14","current":-4.711914,"twenty":-6.064471,"median":-4.705652,"eighty":-3.245278,"marketCap":4697778},{"date":"2025-02-21","current":-4.522596,"twenty":-6.049761,"median":-4.627772,"eighty":-3.258259,"marketCap":4509028},{"date":"2025-02-28","current":-3.707687,"twenty":-6.000655,"median":-4.535397,"eighty":-3.316674,"marketCap":3696564},{"date":"2025-03-07","current":-3.460732,"twenty":-5.929065,"median":-4.501561,"eighty":-3.241954,"marketCap":3450350},{"date":"2025-03-14","current":-1.846098,"twenty":-5.873065,"median":-4.396383,"eighty":-3.213473,"marketCap":2852222},{"date":"2025-03-21","current":-1.508371,"twenty":-5.793429,"median":-4.291207,"eighty":-3.160314,"marketCap":2330433},{"date":"2025-03-28","current":-1.353625,"twenty":-5.705978,"median":-3.977976,"eighty":-3.07146,"marketCap":2091350},{"date":"2025-04-04","current":-0.974631,"twenty":-5.536499,"median":-3.903419,"eighty":-3.030526,"marketCap":1505805},{"date":"2025-04-11","current":-0.980061,"twenty":-5.4398,"median":-3.702849,"eighty":-2.640357,"marketCap":1514194},{"date":"2025-04-17","current":-0.985491,"twenty":-5.322255,"median":-3.619184,"eighty":-1.846098,"marketCap":1522583},{"date":"2025-04-25","current":-0.947483,"twenty":-5.174691,"median":-3.5049,"eighty":-1.520317,"marketCap":1463861},{"date":"2025-05-02","current":-0.687943,"twenty":-5.159991,"median":-3.434137,"eighty":-1.353625,"marketCap":1062872},{"date":"2025-05-09","current":-2.602277,"twenty":-5.095085,"median":-3.375088,"eighty":-1.466019,"marketCap":4020518},{"date":"2025-05-16","current":-0.039201,"twenty":-5.02132,"median":-3.354145,"eighty":-1.299871,"marketCap":60566},{"date":"2025-05-23","current":-0.018499,"twenty":-5.006408,"median":-3.310183,"eighty":-1.057434,"marketCap":28581},{"date":"2025-05-30","current":-0.022023,"twenty":-4.999463,"median":-3.245278,"eighty":-1.021327,"marketCap":34025},{"date":"2025-06-06","current":-0.014912,"twenty":-4.937359,"median":-3.214447,"eighty":-0.978975,"marketCap":23039},{"date":"2025-06-13","current":-0.018851,"twenty":-4.922267,"median":-3.183486,"eighty":-0.945854,"marketCap":29125},{"date":"2025-06-20","current":-0.013358,"twenty":-4.871782,"median":-3.155299,"eighty":-0.895899,"marketCap":20638},{"date":"2025-06-27","current":-2.431375,"twenty":-4.817057,"median":-3.116926,"eighty":-0.895899,"marketCap":3756474},{"date":"2025-07-03","current":-2.428961,"twenty":-4.79003,"median":-3.054617,"eighty":-0.90676,"marketCap":3752744},{"date":"2025-07-11","current":-2.469311,"twenty":-4.75787,"median":-3.036282,"eighty":-0.929565,"marketCap":3815085},{"date":"2025-07-18","current":-3.343916,"twenty":-4.728069,"median":-3.039365,"eighty":-0.942596,"marketCap":5166350},{"date":"2025-07-25","current":-4.793774,"twenty":-4.784488,"median":-3.066787,"eighty":-0.954976,"marketCap":7406381},{"date":"2025-08-01","current":-9.134632,"twenty":-4.922267,"median":-3.137242,"eighty":-0.969039,"marketCap":14113006},{"date":"2025-08-08","current":-8.476938,"twenty":-5.004125,"median":-3.155299,"eighty":-0.973817,"marketCap":13096869},{"date":"2025-08-15","current":-8.18463,"twenty":-5.134029,"median":-3.19779,"eighty":-0.976803,"marketCap":12645253},{"date":"2025-08-22","current":-7.746168,"twenty":-5.410414,"median":-3.21607,"eighty":-0.982233,"marketCap":11967829},{"date":"2025-08-29","current":-7.600014,"twenty":-5.856236,"median":-3.245278,"eighty":-0.987228,"marketCap":11742021},{"date":"2025-09-05","current":-7.819245,"twenty":-6.049761,"median":-3.325781,"eighty":-0.992223,"marketCap":12080733},{"date":"2025-09-12","current":-7.143282,"twenty":-6.209629,"median":-3.343916,"eighty":-1.006667,"marketCap":11036370},{"date":"2025-09-19","current":-10.354516,"twenty":-6.696876,"median":-3.375088,"eighty":-1.026648,"marketCap":11742021},{"date":"2025-09-26","current":-11.070023,"twenty":-7.035762,"median":-3.443585,"eighty":-1.030557,"marketCap":12553406},{"date":"2025-10-03","current":-11.383325,"twenty":-7.364852,"median":-3.487865,"eighty":-1.042883,"marketCap":12908691},{"date":"2025-10-10","current":-13.054272,"twenty":-7.512322,"median":-3.569805,"eighty":-1.058791,"marketCap":14803545},{"date":"2025-10-17","current":-11.174457,"twenty":-7.59231,"median":-3.644879,"eighty":-1.068565,"marketCap":12671834},{"date":"2025-10-24","current":-11.278891,"twenty":-7.731553,"median":-3.707687,"eighty":-1.123948,"marketCap":12790262},{"date":"2025-10-31","current":-10.75672,"twenty":-7.950784,"median":-3.905854,"eighty":-1.280758,"marketCap":12198121},{"date":"2025-11-07","current":-9.567215,"twenty":-8.038476,"median":-3.996712,"eighty":-1.310622,"marketCap":10849222},{"date":"2025-11-14","current":-8.045608,"twenty":-8.360015,"median":-4.312242,"eighty":-1.376104,"marketCap":9123720},{"date":"2025-11-21","current":-6.109399,"twenty":-8.170015,"median":-4.417419,"eighty":-1.474489,"marketCap":6928059},{"date":"2025-11-28","current":-5.587228,"twenty":-8.111553,"median":-4.501561,"eighty":-1.508371,"marketCap":6335917},{"date":"2025-12-05","current":-25.23826,"twenty":-8.403861,"median":-4.535397,"eighty":-1.515701,"marketCap":28620187},{"date":"2025-12-12","current":-21.591766,"twenty":-8.696169,"median":-4.627772,"eighty":-1.520317,"marketCap":24485063},{"date":"2025-12-19","current":-17.597159,"twenty":-9.06593,"median":-4.711914,"eighty":-1.541633,"marketCap":19955178},{"date":"2025-12-26","current":-13.245735,"twenty":-9.27961,"median":-4.754698,"eighty":-1.546299,"marketCap":15020663},{"date":"2026-01-02","current":-14.777436,"twenty":-10.201257,"median":-4.798393,"eighty":-1.579229,"marketCap":16757612},{"date":"2026-01-09","current":-23.341039,"twenty":-10.662157,"median":-4.922267,"eighty":-1.630419,"marketCap":26468738},{"date":"2026-01-16","current":-21.842963,"twenty":-11.038692,"median":-4.999213,"eighty":-1.702674,"marketCap":24769920},{"date":"2026-01-23","current":-22.02569,"twenty":-11.165081,"median":-5.003554,"eighty":-1.780942,"marketCap":24977133},{"date":"2026-01-30","current":-18.441421,"twenty":-11.278891,"median":-5.035187,"eighty":-1.871075,"marketCap":20912571},{"date":"2026-02-06","current":-17.471559,"twenty":-11.383325,"median":-5.167341,"eighty":-1.959036,"marketCap":19812748},{"date":"2026-02-13","current":-19.664289,"twenty":-11.445985,"median":-5.322255,"eighty":-2.161828,"marketCap":22299304},{"date":"2026-02-20","current":-19.158274,"twenty":-11.780175,"median":-5.500199,"eighty":-2.356399,"marketCap":21725483},{"date":"2026-02-27","current":-19.24261,"twenty":-12.048622,"median":-5.587228,"eighty":-2.377712,"marketCap":21821120},{"date":"2026-03-06","current":-19.130163,"twenty":-12.337157,"median":-5.805751,"eighty":-2.404957,"marketCap":21693605},{"date":"2026-03-13","current":-21.491564,"twenty":-13.089202,"median":-5.977481,"eighty":-2.428961,"marketCap":24371434},{"date":"2026-03-20","current":-18.975548,"twenty":-13.87234,"median":-6.068669,"eighty":-2.429444,"marketCap":21518271},{"date":"2026-03-27","current":-6.571741,"twenty":-14.681705,"median":-6.104823,"eighty":-2.432754,"marketCap":21916757},{"date":"2026-04-02","current":-6.133576,"twenty":-14.29878,"median":-6.093857,"eighty":-2.438272,"marketCap":20455475},{"date":"2026-04-10","current":-5.228861,"twenty":-14.168236,"median":-6.058175,"eighty":-2.459999,"marketCap":17438252},{"date":"2026-04-17","current":-5.848317,"twenty":-13.976774,"median":-5.969011,"eighty":-2.460689,"marketCap":19504138},{"date":"2026-04-24","current":-7.906455,"twenty":-13.454603,"median":-6.058175,"eighty":-2.469311,"marketCap":26368026},{"date":"2026-05-01","current":-8.924253,"twenty":-13.245735,"median":-6.093519,"eighty":-2.483106,"marketCap":29762383},{"date":"2026-05-08","current":-7.936411,"twenty":-13.245735,"median":-6.109399,"eighty":-2.496901,"marketCap":26467930},{"date":"2026-05-15","current":-8.430332,"twenty":-13.097935,"median":-6.18242,"eighty":-2.517594,"marketCap":28115156},{"date":"2026-05-22","current":-7.100113,"twenty":-13.054272,"median":-6.295839,"eighty":-2.548287,"marketCap":23678877},{"date":"2026-05-29","current":-9.261017,"twenty":-12.817554,"median":-6.483666,"eighty":-2.548563,"marketCap":30885492},{"date":"2026-06-05","current":-7.184304,"twenty":-12.577356,"median":-6.653598,"eighty":-2.591548,"marketCap":23959654},{"date":"2026-06-12","current":-6.49955,"twenty":-12.378931,"median":-6.640969,"eighty":-2.628587,"marketCap":21675999},{"date":"2026-06-18","current":-7.425652,"twenty":-12.330195,"median":-6.571741,"eighty":-2.650742,"marketCap":24764549},{"date":"2026-06-26","current":-6.409746,"twenty":-12.260573,"median":-6.632,"eighty":-2.70965,"marketCap":21376504},{"date":"2026-07-02","current":-7.116951,"twenty":-12.177025,"median":-6.653598,"eighty":-2.796579,"marketCap":23735032},{"date":"2026-07-10","current":-8.059891,"twenty":-12.10238,"median":-6.750178,"eighty":-2.921331,"marketCap":26879737},{"date":"2026-07-17","current":-7.296559,"twenty":-12.01284,"median":-7.006752,"eighty":-2.995391,"marketCap":24334024},{"date":"2026-07-24","current":-8.593101,"twenty":-11.905496,"median":-7.027147,"eighty":-3.017632,"marketCap":28657992},{"date":"2026-07-31","current":-6.522001,"twenty":-11.884609,"median":-7.027147,"eighty":-3.030526,"marketCap":21750873},{"date":"2026-08-07","current":-6.449035,"twenty":-11.801062,"median":-6.876942,"eighty":-3.037515,"marketCap":21507533},{"date":"2026-08-14","current":-6.033693,"twenty":-11.780175,"median":-6.701609,"eighty":-3.042447,"marketCap":20122366},{"date":"2026-08-21","current":-5.887762,"twenty":-11.696628,"median":-6.632,"eighty":-3.047315,"marketCap":19635685},{"date":"2026-08-28","current":-7.184304,"twenty":-11.654854,"median":-6.571741,"eighty":-3.07146,"marketCap":23959654},{"date":"2026-09-04","current":-7.049598,"twenty":-11.466872,"median":-6.653598,"eighty":-3.098279,"marketCap":23510410},{"date":"2026-09-11","current":-7.086005,"twenty":-11.383325,"median":-6.725893,"eighty":-3.130783,"marketCap":23631828},{"date":"2026-09-18","current":-6.959807,"twenty":-11.383325,"median":-6.750178,"eighty":-3.1437,"marketCap":23210958},{"date":"2026-09-25","current":-7.569932,"twenty":-11.383325,"median":-6.947188,"eighty":-3.147919,"marketCap":25245724},{"date":"2026-10-02","current":-5.469924,"twenty":-11.383325,"median":-6.783131,"eighty":-3.155299,"marketCap":25063193},{"date":"2026-10-07","current":-5.125245,"twenty":-11.383325,"median":-6.750178,"eighty":-3.170343,"marketCap":23483872}],"updateTime":1791491636965},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PLRZ\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2647837100","title":"Polyrizon Makes Strong Progress: Receives Central Irb Approval for Its Allergy Blocker Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2647837100","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647837100?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:44","pubTimestamp":1782737040,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA17TTBM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644278745","title":"Polyrizon says U.S. publishes patent application for Trap & Target nasal drug delivery platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2644278745","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644278745?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:15","pubTimestamp":1781698515,"startTime":"0","endTime":"0","summary":"Polyrizon received notice of publication for U.S. patent application US 2024/0358741 A1 covering its Trap & Target mucoadhesive polymer nasal delivery platform.Application describes biocompatible compositions designed to form a durable film on nasal mucosa to improve retention and drug absorption.Platform targets intranasal delivery formats including sprays and gels, with potential use in localized or systemic administration via mucosal tissues.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL86QfLD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","LU2210149790.SGD","BK4139","BK4585","SG9999014013.SGD","IE00BKPKM429.USD","LU0314104364.USD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4588","NDAQ","IE00BN0W2T93.GBP","SG9999014005.SGD","PLRZ","SG9999014039.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","LU2210150020.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644274527","title":"Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2644274527","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644274527?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:15","pubTimestamp":1781698500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nTUA96ZW9H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643051972","title":"Polyrizon Signs Agreements for Nasarix Human Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2643051972","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643051972?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:46","pubTimestamp":1781527597,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) has entered into agreements with a European university medical center and a clinical research organization to conduct a human study for its Nasarix allergy blocker, the company said M","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203937","title":"Polyrizon - Agrees With European Medical Center and Cro for Nasarix Human Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203937","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203937?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:11","pubTimestamp":1781525485,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nFWN42N0BZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203553","title":"Polyrizon signs contracts with European medical center, CRO for NASARIX nasal residence-time study","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203553","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203553?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:06","pubTimestamp":1781525164,"startTime":"0","endTime":"0","summary":"Polyrizon signed an agreement with a European university medical center to run a human study measuring the nasal residence time of its NASARIX allergy blocker formulation.The company also contracted a clinical research organization to manage study operations and regulatory filings in Europe.The study is intended to support Polyrizon’s verification and validation program and its planned FDA submissions.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL4x4lXs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NDAQ","SG9999014013.SGD","LU2210149790.SGD","IE00BN0W2T93.GBP","SG9999014039.USD","SG9999014005.SGD","BK4112","BK4585","LU2095319765.USD","IE00B64PRP62.GBP","SG9999014021.USD","LU2210150020.SGD","PLRZ","IE00BN0W2V16.EUR","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4139","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642232614","title":"Polyrizon says European patent application for mucoadhesive nasal drug delivery technology is published","url":"https://stock-news.laohu8.com/highlight/detail?id=2642232614","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642232614?lang=en_us&edition=fundamental","pubTime":"2026-06-10 19:47","pubTimestamp":1781092038,"startTime":"0","endTime":"0","summary":"Polyrizon received notice that the European Patent Office completed technical preparations to publish its “Mucoadhesive Polymers for Nasal Drug Delivery” application.The application, published as EP 4751737, covers the Trap & Target mucoadhesive polymer platform for intranasal drug delivery.The technology targets longer nasal residence time to support higher formulation retention and improved absorption, aiming to strengthen partnering and commercialization options.The filing now moves into the European examination process, with potential patent protection across multiple European markets if granted.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDLb1s17j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BKPKM429.USD","SG9999014039.USD","LU0314104364.USD","IE00BN0W2W23.USD","LU2095319765.USD","LU2210149790.SGD","PLRZ","SG9999014021.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4139","BK4585","SG9999014005.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","NDAQ","BK4112","IE00BN0W2V16.EUR","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642423280","title":"Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2642423280","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642423280?lang=en_us&edition=fundamental","pubTime":"2026-06-10 19:47","pubTimestamp":1781092020,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nTUA1CSFHC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642343138","title":"Polyrizon announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642343138","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642343138?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:01","pubTimestamp":1780948883,"startTime":"0","endTime":"0","summary":"Polyrizon will hold its annual general meeting in Raanana, Israel on July 13, 2026.Shareholders will vote on re-electing Class II directors Liat Sidi, Yehonatan Zalman Vinokur, with terms running to the 2029 AGM.Ballots also cover an amended executive and director compensation policy, including higher caps for annual equity awards, cash bonus limits.Equity grants are up for approval, including RSUs for directors, Chairman Oz Adler, CEO Tomer Izraeli, CTO Tidhar Turgeman.Other items include higher non-executive director fees, an exchange-rate floor of NIS 3.5 per USD for chairman pay, auditor reappointment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via E","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL9BcdWh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641372480","title":"Polyrizon signs deals with two additional US clinical sites for NASARIX trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2641372480","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641372480?lang=en_us&edition=fundamental","pubTime":"2026-06-08 22:22","pubTimestamp":1780928548,"startTime":"0","endTime":"0","summary":"Polyrizon signed agreements with two additional U.S. clinical sites for its NASARIX  seasonal allergic rhinitis trial, bringing the total to three.The three sites are expected to deliver the highest patient enrollment in the planned multi-center U.S. study.The trial will assess safety, tolerability, and efficacy of NASARIX compared with saline spray, with up to five sites planned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief on June 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL3h2HzS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641915487","title":"Polyrizon Advances Nasarix Study With 3 Major US Trial Sites","url":"https://stock-news.laohu8.com/highlight/detail?id=2641915487","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641915487?lang=en_us&edition=fundamental","pubTime":"2026-06-08 21:51","pubTimestamp":1780926678,"startTime":"0","endTime":"0","summary":"Polyrizon  has secured agreements with three US clinical sites for its upcoming Nasarix trial, marking a key step toward initiating its multi-center study in seasonal allergic rhinitis, the company said Monday.The sites represent major enrollment centers expected to support patient recruitment for the study evaluating the safety, tolerability and efficacy of its intranasal hydrogel allergy blocker.Polyrizon said the trial will compare Nasarix with saline spray in patients with seasonal allergic rhinitis, with up to five US sites expected to participate in total.Shares of Polyrizon were down more than 3% in Monday trading.Price: 12.73, Change: -0.48, Percent Change: -3.63","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641580487","title":"Polyrizon signs agreements with two additional clinical sites for Nasarix study","url":"https://stock-news.laohu8.com/highlight/detail?id=2641580487","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641580487?lang=en_us&edition=fundamental","pubTime":"2026-06-08 21:37","pubTimestamp":1780925839,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) announced it has signed agreements with two additional U.S. clinical sites. This brings the total to three major contracted sites ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-signs-agreements-with-two-additional-clinical-sites-for-nasarix-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-signs-agreements-with-two-additional-clinical-sites-for-nasarix-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641348221","title":"Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for Nasarix™ Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2641348221","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641348221?lang=en_us&edition=fundamental","pubTime":"2026-06-08 21:25","pubTimestamp":1780925100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nTUA87LTMG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641914704","title":"Polyrizon: Co & Arrow Aviation Entered Into Letter Agreement Extending Exclusivity Period & Initial Negotiation Period Under Mou to June 30","url":"https://stock-news.laohu8.com/highlight/detail?id=2641914704","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641914704?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:24","pubTimestamp":1780691049,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nFWN42D0IJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638636309","title":"Polyrizon appoints Ami Oren as Class I director","url":"https://stock-news.laohu8.com/highlight/detail?id=2638636309","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638636309?lang=en_us&edition=fundamental","pubTime":"2026-05-28 04:26","pubTimestamp":1779913603,"startTime":"0","endTime":"0","summary":"Polyrizon appointed Ami Oren as a Class I director, effective May 14, 2026.Oren, 51, founded and ran Hummus Ami from 2015 to 2026, overseeing finance, procurement, staffing, customer experience.He exited the business through a sale; earlier operated an independent catering and culinary operation for large-scale events.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL3bLwkk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635975780","title":"Polyrizon signs first U.S. clinical trial agreement for NASARIX allergy blocker study","url":"https://stock-news.laohu8.com/highlight/detail?id=2635975780","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635975780?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:25","pubTimestamp":1778678740,"startTime":"0","endTime":"0","summary":"Polyrizon signed first U.S. clinical trial agreement with an allergy-focused clinical research site in Texas to start human testing of NASARIX  seasonal allergic rhinitis nasal spray.Texas site set to serve as first center in planned multi-center study comparing PL-14 efficacy, safety, tolerability versus saline spray.Agreement marks initial U.S. site activation step ahead of planned first-in-human clinical program; additional sites expected in coming months.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL1lwgMf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","LU0314104364.USD","BK4585","PLRZ","LU2095319765.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014039.USD","SG9999014005.SGD","BK4112","BK4588","IE00BN0W2W23.USD","LU2210149790.SGD","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BGHQF748.EUR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635780617","title":"Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for Nasarix™ Allergy Blocker Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2635780617","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635780617?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:25","pubTimestamp":1778678700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nTUA68YTHG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632955811","title":"Polyrizon expands U.S. patent claims for intranasal drug delivery platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2632955811","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632955811?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:54","pubTimestamp":1777899256,"startTime":"0","endTime":"0","summary":"Polyrizon submitted amended claims in a U.S. patent application to broaden protection for its intranasal drug-delivery hydrogel platform beyond core mucoadhesive composition to cover drug-delivery systems and methods of use.Claims target formulations using sulfated polysaccharide polymers with additional polymer components designed to form a continuous film on contact with nasal mucosa, aiming to increase drug residence time and improve bioavailability.Move supports strategy to strengthen intellectual property position for intranasal delivery across local and systemic drug administration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electron","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL11KcPG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630585230","title":"Polyrizon Ltd trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2630585230","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630585230?lang=en_us&edition=fundamental","pubTime":"2026-04-28 22:31","pubTimestamp":1777386663,"startTime":"0","endTime":"0","summary":"09:58 EDT Polyrizon (PLRZ) Ltd trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-movin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-ltd-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-ltd-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630058825","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:58 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2630058825","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630058825?lang=en_us&edition=fundamental","pubTime":"2026-04-28 21:58","pubTimestamp":1777384732,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:58 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nAQN2LWI02:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":44,"code":"91000000","status":"200"}]}}